Table 2 Univariate and multivariate survival analyses for progression-free survival (PFS) and overall survival (OS) of the patients with high-grade serous ovarian carcinoma.
From: Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas
Variables | Univariate PFS analysis | P value | Multivariate PFS analysis | P value |
|---|---|---|---|---|
HR (95% CI) | HR (95% CI) | |||
Age (< 60 years vs. ≥ 60 years) | 1.111 (0.654–1.888) | 0.697 | ||
2014 FIGO stage (I and II vs. III and IV) | 8.101 (2.511–26.140) | < 0.001 | 6.698 (1.890–23.732) | 0.003 |
CA125 level before initial treatment* | 1.936 (1.126–3.327) | 0.017 | 0.977 (0.552–1.727) | 0.935 |
Architectural grade (1 and 2 vs. 3) | 0.717 (0.409–1.258) | 0.246 | ||
Nuclear grade (2 vs. 3) | 1.302 (0.518–3.274) | 0.575 | ||
Intra-tumoral Budding (presence vs. absence) | 1.452 (1.093–1.928) | 0.010 | 1.094 (0.804–1.488) | 0.568 |
Lymph vascular space invasion (presence vs. absence) | 1.909 (1.085–3.359) | 0.025 | 1.338 (0.736–2.434) | 0.340 |
Mitoses (≤ 12 vs. > 12)** | 0.741 (0.417–1.320) | 0.309 | ||
Lymph node metastasis (presence vs. absence) | 1.368 (0.723–2.588) | 0.336 | ||
p53 expression (overexpression vs. complete absence) | 0.902 (0.503–1.618) | 0.729 |
Variables | Univariate OS analysis | P value | Multivariate OS analysis | P value |
|---|---|---|---|---|
HR (95%CI) | HR (95%CI) | |||
Age (< 60 years vs. ≥ 60 years) | 0.891 (0.449–1.767) | 0.741 | ||
2014 FIGO stage (I and II vs. III and IV) | 8.392 (1.146–61.472) | 0.036 | 4.927 (0.570–42.608) | 0.147 |
CA125 level before initial treatment* | 2.283 (1.082–4.819) | 0.030 | 1.516 (0.700–3.282) | 0.291 |
Architectural grade (1 and 2 vs. 3) | 0.591 (0.280–1.245) | 0.167 | ||
Nuclear grade (2 vs. 3) | 0.903 (0.317–2.571) | 0.848 | ||
Intra-tumoral budding (presence vs. absence) | 1.463 (0.984–2.176) | 0.060 | 1.173 (0.773–1.781) | 0.453 |
Lymph vascular space invasion (presence vs. absence) | 1.409 (0.691–2.873) | 0.346 | ||
Mitoses (≤ 12 vs. > 12)** | 0.608 (0.293–1.264) | 0.183 | ||
Lymph node metastasis (presence vs. absence) | 1.055 (0.431–2.584) | 0.907 | ||
p53 expression (overexpression vs. complete absence) | 0.886 (0.390–2.010) | 0.772 |
